Jasper Therapeutics, Inc. (JSPR)

Market Cap	50.02M
Revenue (ttm)	n/a
Net Income (ttm)	-78.78M
Shares Out	15.02M
EPS (ttm)	-5.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	350,325
Open	3.400
Previous Close	3.370
Day's Range	3.264 - 3.480
52-Week Range	2.265 - 26.050
Beta	2.70
Analysts	Buy
Price Target	31.67 (+851.05%)
Earnings Date	Aug 12, 2025

About JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: JSPR
• Website: https://jaspertx.com

Analyst Summary

According to 12 analysts, the average rating for JSPR stock is "Buy." The 12-month stock price target is $31.67, which is an increase of 851.05% from the latest price.

Price Target

$31.67

(851.05% upside)

Analyst Consensus: Buy